Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials

<bold>Introduction:</bold> Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments. <bold>Aim:</bold> To assess which trial outcomes for exacerbation treatments are most important for patients with COPD. <bold>Methods:</bold> Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials. Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year. <bold>Results:</bold> Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male). 45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%). Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function (Figure 1). Dyspnoea was most prioritised in both groups. <fig><object-id>erj;66/suppl_69/PA356/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Conclusions:</bold> COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea. The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.

Authors

Institutions

Publication Details

Published
2025-09-27
DOI
https://doi.org/10.1183/13993003.congress-2025.pa356
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials

Guy Brusselle, Elizabeth Stovold, Zeineb Hammouda, Gerard J. Criner et al.
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials

Guy Brusselle, Elizabeth Stovold, Zeineb Hammouda, Gerard J. Criner, Janelle Yorke, Marco Contoli, Isabel Saraiva, Sachin Ananth, Zsófia Lázár, Courtney Coleman, Balázs Csoma, Thomas Bradbury, Alejandra López-Giraldo, Gustavo Fernandez Romero, Alberto Papi, Guy Joos, John Linnell, Jens‐Ulrik Stæhr Jensen, Cordula Cadus, Galina Sergeeva, Christine Jenkins, Bianca Beghé, Per Bakke, Àlvar Agustí, Rosa Faner, Alexander G. Mathioudakis, András Bikov, Jörg D. Leuppi, Κonstantinos Bartziokas, Olga Corlateanu, Arturo Huerta, Vanessa M. McDonald, Alexandru Corlăteanu, Alexander Emelyanov, Michael R. Jacobs, Fekri Abroug, Péter Horváth, Agni Sioutkou, Paula Ruth Williamson, Carol Liddle, Hao Wang, Olga Kharevich, Jørgen Vestbo, Pradeesh Sivapalan, Fuqiang Wen, Rune Nielsen, Konstantinos Kostikas, Elena Lapteva
article en

Abstract

<bold>Introduction:</bold> Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments. <bold>Aim:</bold> To assess which trial outcomes for exacerbation treatments are most important for patients with COPD. <bold>Methods:</bold> Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials. Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year. <bold>Results:</bold> Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male). 45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%). Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function (Figure 1). Dyspnoea was most prioritised in both groups. <fig><object-id>erj;66/suppl_69/PA356/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Conclusions:</bold> COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea. The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.

Semmelweis University (HU), University of Modena and Reggio Emilia (IT), University of Copenhagen (DK), St George's, University of London (GB), University of Ioannina (GR), University of Ferrara (IT), Sichuan University (CN), Manchester Academic Health Science Centre (GB), Haukeland University Hospital (NO), Ghent University Hospital (BE), British Lung Foundation (GB), University Hospital of Basel (CH), Gentofte Hospital (DK), West China Hospital of Sichuan University (CN), Kantonsspital Baselland (CH), Lung Institute (US), The George Institute for Global Health (AU), Nicolae Testemițanu State University of Medicine and Pharmacy (MD), The Christie NHS Foundation Trust (GB), North-Western State Medical University named after I.I. Mechnikov (RU), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Hospital Fatuma Bourguiba Monastir (TN), University of Bergen (NO), Belarusian State Medical University (BY), Liverpool John Moores University (GB), Universitat de Barcelona (ES), Saint Petersburg State Pediatric Medical University (RU), University of Newcastle Australia (AU), IT University of Copenhagen (DK), Temple University (US)
Openalex Percentile: Top 48%
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.